Jump to Main Content
- Salamin, Olivier; Kuuranne, Tiia; Saugy, Martial; Leuenberger, Nicolas
- Molecular and cellular endocrinology 2018 v.464 pp. 75-87
- adverse effects; athletes; biomarkers; drugs; erythrocytes; erythropoiesis; erythropoietin; humans; marketing; patient compliance; patients; pharmaceutical industry; risk; sports; transcriptomics
- ... Erythropoietin (EPO) is the main hormone regulating red blood cell (RBC) production. The large-scale production of a recombinant human erythropoietin (rHuEPO) by biotechnological methods has made possible its widespread therapeutic use as well as its misuse in sports. Since the marketing of the first epoetin in 1989, the development has progressed to the third-generation analogs. However, the prod ...